The Patent Finder

Amidebio, LLC

5 patents currently held · Updated Nov 21, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Nov 2030
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Apr 20, 2027
    The maintenance fee for Chemically and thermodynamically stable insulin analogues and improved methods for their production (US 9,163,073) comes due Apr 20, 2027. Unpaid by Oct 20, 2027, it lapses early.
  • 1 fee due Aug 23, 2027
    The maintenance fee for Efficient Production of Peptides (US 9,266,934) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 5 of 5

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,796,431Efficient Production of Peptides
In force
 · High confidence
In forceHigh confidence
US 9,266,934Efficient Production of Peptides
In force
 · High confidence
In forceHigh confidence
US 9,006,176Chemically and Thermodynamically Stable Insulin Analogues and Improved Methods for Their Production
In force
 · High confidence
In forceHigh confidence
US 9,163,073Chemically and thermodynamically stable insulin analogues and improved methods for their production
In force
 · USPTO record
In forceUSPTO record
US 11,179,444Glucagon analogs and methods of use thereof
In force
 · USPTO record
In forceUSPTO record
Also on record, not counted in the 5: 1 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

7 abandoned · 4 no status recorded

Showing 1 to 10 of 11, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
18/618,780Glucose-Responsive Insulin Analogs and Methods of Use ThereofMar 27, 2024Abandoned
17/213,765Glucose-Responsive Insulin Analogs and Methods of Use ThereofMar 26, 2021Abandoned
15/815,370Efficient Production of PeptidesNov 16, 2017Abandoned
15/689,140Aug 29, 2017No status recorded
16/084,934Mar 16, 2017No status recorded
15/002,259Efficient Production of PeptidesJan 20, 2016Abandoned
14/846,063Sep 4, 2015No status recorded
14/752,461Jun 26, 2015Abandoned
14/657,804Mar 13, 2015No status recorded
14/219,792Mar 19, 2014Abandoned
10 of 11 applications shown.
Pro members see all 11 published applications.
Pro members: see all 11 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited